By Steve Usdin
Contributing Editor

WASHINGTON - Legislation to limit FDA's ability to prohibit manufacturers from disseminating information about unapproved uses of approved drugs, biologicals and medical devices will be completed this week and will be offered as an amendment to legislation reauthorizing the Prescription Drug User Fee Act (PDUFA), according to a congressional aide working on the bill.